《原发性肝癌诊疗规范(2017年版)》解读

Interpretation of Specifications for Diagnosis and Treatment of Primary Liver Cancer(2017 Edition)

肝癌是全球高发病率的恶性肿瘤之一,也是我国第三大肿瘤致死病因。肝炎和肝硬化背景是我国肝癌患者的一大特点,对我国肝癌的筛查诊断、治疗方式选择、预后随访等诸多防治环节提出了切合国情的具体要求。《原发性肝癌诊疗规范(2017年版)》依据中国实践,提出符合中国国情的肝癌分期,并形成以外科手术治疗为主的多学科联合诊治模式,将肝移植术纳入肝癌外科治疗手段,强调循证医学的证据支持,为未来中国肝癌诊治及研究的进步奠定了坚实的基础。

Liver cancer is one of the world＇s most prevalent malignancies, and is also the third leading cause of cancer death in China. Hepatitis and cirrhosis background is a major feature of liver cancer patients in China, which makes specific requirements that suits the national conditions in many aspects of prevention and control like screening diagnosis, treatment options, and prognosis follow-up. The Specifications for Diagnosis and Treatment of Primary Liver Cancer （2017 Edition）, which is based on China＇s practice, proposes liver cancer staging in line with China＇s national conditions and forms a multi-disciplinary joint diagnosis and treatment model based on surgical treatment. Liver transplantation is included in liver cancer as one of the surgical treatments option. It also emphasizes the support of evidence-based medicine. The Specifications for Diagnosis and Treatment of Primary Liver Cancer （2017 Edition） may have laid a solid foundation for future diagnosis and treatment of liver cancer in China.